Montelukast oral film - IntelGenx

Drug Profile

Montelukast oral film - IntelGenx

Alternative Names: INT 0043/2015; INT0043; Montelukast repurposed - IntelGenx; Montelukast VersaFilm

Latest Information Update: 11 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IntelGenx Corp.
  • Class Acetates; Antiasthmatics; Quinolines; Small molecules
  • Mechanism of Action Leukotriene D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Alzheimer's disease; Mild cognitive impairment

Highest Development Phases

  • Phase I Alzheimer's disease; Mild cognitive impairment

Most Recent Events

  • 09 Nov 2017 IntelGenx filed a Clinical Trial Application for a planned phase IIa proof-of-concept trial
  • 09 Nov 2017 IntelGenx plans a phase IIa proof-of-concept trial for Alzheimer's disease in Canada
  • 22 Aug 2016 Pharmacokinetics data from a phase I trial in Healthy volunteers released by IntelGenx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top